StockData
REVBNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as REVBW

REVELATION BIOSCIENCES, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.29+2.80 (+577.76%)

Close on Oct 19, 2026

Market cap
$12.58M
P/E (TTM)
–
Dividend yield
–

REVELATION BIOSCIENCES, INC. revenue by segment

No segment breakdown reported

Revelation Biosciences does not break out revenue by segment, region or product in the tagged data of its filings for this period type.